HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

THE FDA MAKES HEPATITIS C A PRIORITY

6/17/2013

3 Comments

 
June 14, 2013
The FDA Makes Hepatitis C a Priority
by Benjamin Ryan                    
Recognizing that investigational
drugs from three pharmaceutical companies show advantages over existing
hepatitis C therapies, the FDA has sped up its development and review process
for the therapies.


With pharmaceutical companies clamoring to bring to market second-generation direct
acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV), the U.S.
Food and Drug Administration (FDA) has recently given a trio of companies a
significant leg up. Two promising investigational agents—Gilead Sciences’
nucleotide analogue inhibitor sofosbuvir and Janssen’s protease inhibitor
simeprevir—each received what is known as a priority review status from the FDA
over the past few weeks. And in early May, the FDA tapped AbbVie’s
interferon-free combination therapy, ABT-450/r, ABT-267 and ABT-333 (which has
been studied both with and
without ribavirin) as a “breakthrough therapy,” qualifying those drugs for an
expedited development and review process in preparation for FDA approval.


The FDA grants priority review to drugs in development that appear to
offer significant advantages over available therapies. As of now, there are two
FDA-approved DAAs to treat hep C: Incivek (telaprevir) and Victrelis
(boceprevir), each of which cures about 50 to 75 percent of those who undergo
therapy lasting between 24 and 48 weeks. Both must be taken with ribavirin and
also interferon, an injectable drug that often causes difficult, flu-like side
effects. So at this stage, the FDA’s imprimatur for the investigational
therapies, while not necessarily a promise of the final stamp of approval, marks
an official recognition that the research indicates these new drugs will likely
improve on the current crop of therapeutic options on various fronts.


Simeprevir, for one, has shown in clinical trials to have
somewhat higher cure rates than today’s DAAs, but its major advancements are in
its once-a-day dosing, its reduction of side effects and its shorter duration of
therapy. Sofosbuvir, meanwhile, has been a champion of sorts throughout the
clinical trials process, consistently boasting high cure rates when used in
combination with other drugs in development: either Bristol-Myers Squibb’s daclatasvir or Gilead’s
own ledipasvir (the company
has longer-range plans to develop sofosbuvir and ledipasvir as a fixed-dose
pill).

For practical purposes, the priority review is intended to cut
down the FDA’s review process, which begins 60 days after a new drug application
(NDA) is filed, from the standard 10 months to six. Companies that receive
priority review also get additional guidance from the FDA to expedite the
development and approval process. On March 28, Janssen filed its NDA for
simeprevir, to be taken with ribavirin and interferon for treatment of those
with genotype 1 of hep C; as such, the company expects an answer from the FDA in
late November. Gilead is just a couple
weeks behind in the same process; it’s seeking approval for sofosbuvir to be
administered as an all-oral therapy with ribavirin among those with genotype 2
or 3, and in combination with ribavirin and interferon for genotypes 1, 4, 5 and
6.

By comparison, Incivek and Victrelis each received priority review
designation in January 2011 and were approved in May that same year.


Achieving breakthrough therapy status, on the other hand, promises a more
dynamic range of benefits to AbbVie, which is the first company developing an
HCV therapy that has received the designation. Intended to expedite the
development and review of investigational drugs when clinical trial data shows
they promise at least one significant improvement over currently available
treatments, the designation means AbbVie receives, for starters, fast track
designation. This allows a pharmaceutical company to submit elements of its
marketing application before submitting its complete application for the drug.
Among other benefits, the breakthrough therapy designation also grants AbbVie
more FDA involvement in the combo therapy development—for example, by providing
increased access to the agency’s senior management, as well as giving practical
advice and helping design clinical trials that are as efficient as
possible.

Alan Franciscus, executive director of the Hepatitis C Support
Project in San Francisco, said that AbbVie’s breakthrough status was awarded
“clearly because of the less frequent dosing and pill burden, lower side effects
and high cure rates” when compared with Incivek and Victrelis.

“I
believe that this will greatly accelerate the approval process, especially if
the FDA has stated that they will provide guidance during the development and
approval process,” Franciscus says.

But even with all this extra help,
AbbVie’s combo is still running behind its competitors, not having submitted an
NDA. Furthermore, sofosbuvir and simeprevir have been researched as an interferon-free combination
therapy with one another: Taken with or without ribavirin, they were found in a
recent study to boast high cure rates among those with genotype 1 of hep C. If
both drugs receive FDA approval, clinicians are free to prescribe them together
off-label, providing yet another option outside the FDA-sanctioned uses for
people with hep C.

Daniel Fierer, MD, an assistant professor of medicine
in infectious diseases at Mount Sinai School of Medicine in New York City,
projects that “since simeprevir and sofosbuvir were already expected to hit the
market soonest, probably at the same time, the only thing I can see is that
maybe AbbVie moves up its timeline a little. But if it doesn’t move it up to
being out before [Janssen’s simeprevir and Gilead’s sofosbuvir] come to the
table, they will start eating without AbbVie, and then it’ll be leftovers for
lunch.”

Indeed, there is much excitement over these drugs in the
pipeline, as well as over the larger wave of interferon-free regimens that
should arrive a bit further down the line. Franciscus acknowledges this but also
hopes that the hubbub doesn’t distract physicians from the hep C patients who
have urgent therapeutic needs.

“What really scares me is that people with
HCV and their medical providers are waiting for the interferon-free drug
approval, but there are definitely some people who should be treated now—it
could be dangerous to wait,” he says. “There is never a guarantee that the
interferon-free drugs will work for
everyone.”  






Search: Hepatitis C virus, HCV, hep C, priority review, fast track, breakthrough therapy, U.S. Food and Drug Administration, FDA, AbbVie, Gilead Sciences, Bristol-Myers Squibb, sofosbuvir, daclatasvir, ABT-450/r, ABT-267, ABT-333, ribavirin, interferon, Incivek, telaprevir, Victrelis, boceprevir, simeprevir, Alan Franciscus,  Daniel Fierer. 


3 Comments
bestessays au reviews link
6/25/2013 09:37:45 pm

This is a really quality post.I find this information. Thank you

Reply
Avail Research DeLand link
7/3/2013 06:25:50 am

This is good to hear! Especially now with the U.S. Preventive Services Task Force backing the CDC's recommendation for baby boomers to get tested for HCV. At the very least, there will be a host of new patients identified who will be needing treatment for varying complications as a result of this deadly infection. In particular, I am still interested to hear more about the new interferon-free medications that some of the big drug companies have been developing. Apparently, they have produced very impressive results in clinical studies.

Reply
Ella link
2/7/2014 03:02:51 pm

Thanks, you helped me a lot, the information for me was very helpful

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy